New treatment paradigm of combined raloxifene and conjugated estrogen for postmenopausal symptoms in VCD-induced menopausal rats by Emam, Marwa N. & Abo El Gheit, Rehab E.
Alexandria Journal of Medicine (2017) 53, 227–236HO ST E D  BY
Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
http://www.elsevier.com/locate/ajmeORIGINAL ARTICLENew treatment paradigm of combined raloxifene
and conjugated estrogen for postmenopausal
symptoms in VCD-induced menopausal rats* Corresponding author. Tel.: +20 1224089068; fax: +20
1276640441.
E-mail addresses: maroo_drmaroo@yahoo.com (M.N. Emam),
extrasystole.2003@gmail.com (R.E. Abo El Gheit).
Peer review under responsibility of Alexandria University Faculty of
Medicine.
http://dx.doi.org/10.1016/j.ajme.2016.06.002
2090-5068  2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Marwa N. Emam *, Rehab E. Abo El GheitPhysiology Department, Faculty of Medicine, Tanta University, EgyptReceived 20 February 2016; revised 25 May 2016; accepted 3 June 2016




Vulvar/vaginal atrophyAbstract Introduction: The decreased ovarian estrogen production that occurs at menopause,
results in osteoporosis and climacteric manifestations, and decreases women’s quality of life. The
hormone replacement therapy (HRT) is the primary treatment options but has been associated with
increased oncogenic potential. The tissue selective estrogen complex (TSEC) is a novel therapy,
partnering a selective estrogen receptor modulator (SERM) with one or more estrogens.
Aim: Our study was done to evaluate the potential relative estrogenic agonist activities of a SERM,
raloxifene (RLX), when dosed alone and its antagonist activities when paired with conjugated estro-
gen (CE), as a TSEC and its potential use for the postmenopausal osteoporosis, vulvar/vaginal atro-
phy (VVA) in VCD induced menopausal rat model.
Material and methods: Female rats were dosed daily with 4-vinylcyclohexene diepoxide (VCD)
(80 mg/kg/d, IP) for 15 days to induce ovarian failure, followed by one month free drug. VCD
injected rats received 12 weeks of RLX, CE, or combined RLX/CE with 17b-estradiol (E2), vehicle
treated groups used as positive and negative controls, respectively. The bone turnover markers
(BTM) were measured. The uterotropic activity was assessed by the uterine index and peroxidase
assay. Vaginal wet weight (wt.) and glycogen were measured to evaluate the vaginotropic effects.
Uterine and vaginal (ER) protein levels were assayed.
Results: Our findings showed that the appropriate RLX/CE dose combination exhibits significant
bone sparing with minimal vaginal stimulation and neutral uterine effect.
Conclusion: We can conclude that appropriate RLX/CE combination could effectively be a
promising alternative for the prevention of postmenopausal osteoporosis and VVA with no onco-
genic risk.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The menopausal transition is characterized by gradual
ovarian follicle depletion, with dramatic decrease in the
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effects including vasomotor instability, VVA, mood changes
and a substantial increase in bone turnover, eventually osteo-
porosis and bone fractures with increased risk of cardiovascu-
lar and cerebrovascular complications.1
Under menopausal hypoestrogenism, the tissues of the
vulva and the lining of the vagina become thinner, drier, and
less elastic, a condition known as VVA. Unlike vasomotor
symptoms, VVA typically worsen without treatment and can
significantly impact the quality of life.2
Unlike the ovariectomy (OVX) model, which parallels with
surgically-induced menopause in humans, VCD induced ovar-
ian failure rat model provides a more physiologically relevant
model, that resembles the natural and transitional menopause,
in which there is a gradual rather than abrupt decline of sex
hormones.3
Although hormone replacement therapy (HRT) with exoge-
nous estrogen may effectively offset the menopausal symp-
toms, some women are susceptible to hormone-dependent
neoplasias.4
CE is the most widely used estrogen for HT, comprised of
estrone sulfate and at least ten other hormones. Estradiol is the
most potent and natural human form of estrogen in pre-
menopausal women, comprised of 17b-estradiol. The estrone
(ER) binding potency is approximately ⅔ the affinity of estra-
diol to the ERa and about ⅓ the potency of estradiol for ERb.
Additionally, estrone and estradiol likely have differential
potencies for membrane mediated actions.4
Continued efforts to provide women with efficacious meno-
pausal therapies have generated interest in the development of
SERMs. Similar to estrogens, SERMs have been shown to
bind to ERs with high affinity, despite lacking the estrogen
steroid moiety and to regulate transcriptional events in a vari-
ety of target tissues.5
Whereas estrogens typically exhibit ER agonist effects in all
tissues, SERMs demonstrate mixed functional activity (ER
agonist/antagonist) depending on the target tissue. Unfortu-
nately, they do not provide relief from climacteric symptoms.5
RLX is a second generation SERM. It is the only SERM
actually approved internationally by the Food and Drug
Administration (FDA) for the prevention and treatment of
postmenopausal osteoporosis, with added benefit of prevent-
ing breast cancer.6
Currently RLX is undergoing clinical investigation for the
management of postmenopausal conditions associated with
estrogen deficiency, as the most attractive SERMs with accept-
able safety and tolerability.7
To date, no SERM alone has been able to achieve an ideal
balance of ER agonist and antagonist activity for an optimal
menopausal therapy that would act as an ER agonist by pre-
serving the positive estrogenic effects on bone, CNS and lipid
metabolism, while acting as an ER antagonist by maintaining
breast and endometrial safety. However, it may be possible to
achieve optimal results based on the blended tissue-selective
activities of a SERM and estrogens in a novel approach termed
(TSEC).8
The goal of the present study was to investigate the effects
of combined RLX/CE, as TSEC, on the bone and reproductive
organs in VCD-treated rats, after selection of the appropriate
dose combination depending upon uterine weight.2. Material and methods
Three-months-old albino female rats (weight: 250 ± 10 g)
were purchased from the Faculty of Science, Tanta University.
The rats were acclimatized to the controlled laboratory condi-
tions for one week and appropriately housed, four per cage, at
a constant temperature of 22 ± 2 C and 12 h artificial light/-
dark cycle. All rats had free access to food pellets and water
throughout the study period. All the animal experiments were
conducted according to the guidelines established by the
Research Advisory Ethical Committee of Faculty of Medicine,
Tanta University, Egypt.
All experimental animals were injected with VCD, except
control normal group. All treatments (obtained from Sigma,
St Louis, MO, USA) were started, one month after induction
of ovarian failure, continued for 12 week and were adminis-
tered orally (by gavage) in a vehicle of 2%Tween 80/0.5%
methylcellulose with the exception of E2, which was delivered
I.P., dissolved in distilled water with 1% dimethyl sulfoxide
(DMSO) and 0.1% Tween 20.1
2.1. Chemical induction of ovarian failure
After acclimation, the occupational chemical 4-
vinylcyclohexene diepoxide (VCD) (96% purity, Sigma–
Aldrich, St Louis, MO) was administered at a dose of
(80 mg/kg/day, IP; 5 times per week; for 15 days) dissolved
in sesame oil (2.5 mL/kg), followed by a drug-free period of
30 days. The control group dosed with sesame oil (2.5 mL/
kg). Body weights were checked twice weekly throughout the
period of induction to adjust the VCD dose. VCD specifically
causes gradual apoptotic cell death of primordial and primary
follicles resulting in induced ovarian failure without evidence
of systemic toxicity, resulting in an endocrine state that closely
mimics the natural modeling the transition to menopause in
women.9
2.2. Vaginal smear
After the injection period was completed, the estrous cycles
were monitored daily by obtaining vaginal smears and evaluat-
ing samples microscopically using a standard light microscope
at 100 magnitude to ensure loss of cycling and validating
ovarian failure. The rats are considered acyclic with persistent
diestrus phase, which is dominated by leukocytes, while con-
trol animals showed regular estrous cycles.92.3. Experiment I: determination of minimally efficacious CE
dose
An initial study was conducted on, 80 female albino rats, to
determine the appropriate CE dose to elicit an increase in uter-
ine wet wt., a surrogate measure for an estrogenic stimulatory
response. The VCD treated rats were randomly assigned into
seven groups, 10 rats each, dosed with vehicle, 0.05, 0.5, 2.5,
5 or 10 mg/kg/d of CE and E2 (5 lg/kg/d) was included as a
positive control, for 2 weeks. The minimal officious CE dose
would then be used in the second experiment.
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antagonist dose of RLX
This subsequent study was conducted on, 70 female albino rats,
to determine the minimum fully effective antagonist dose on
the uterine wt. for RLX. Three VCD treated groups, 10 rats
each, were dosed with three doses of RLX (0.3, 3 and 10 mg/
kg/d), combined with 0.5 mg/kg/d of CE for 2 weeks. The min-
imum fully antagonist RLX dose would then be tested in sub-
sequent study for assessment of the effect on bone and
climacteric symptoms.
2.5. Experiment III: to determine the relative estrogenic and
antiestrogenic effects of RLX, on the bone and climacteric
symptoms and its potential therapeutic effect, as a TSEC, when
combined with CE
After establishment of the ovarian failure, fifty VCD treated
female rats, divided into 5 groups, 10 rats each, Vehicle treated
VCD, E2 treated VCD: E2 was given in a dose of 5 lg/kg/d,
CE treated VCD: CE was given in a dose of 0.5 mg/kg/d,
RLX treated VCD: RLX was given in a dose of 10 mg/kg/d
and combined RLX and CE treated VCD groups, received
RLX (10 mg/kg/d) and CE (0.5 mg/kg/d). All treatments con-
tinued for 12 weeks.
At the end of experiment III, all rats were weighed and their
body weights were recorded. Each rat was individually housed
in a metabolic cage without food for 24 h. A urine sample was
collected and acidified with 2 mL of 1 mol/L HCl, stored at
20 C until further analysis, and then all rats were sacrificed.
Blood sample was collected, and then centrifuged at 2000g for
10 min. Serum samples were stored at 80 C until further
analysis.
2.5.1. Biochemical markers of bone metabolism
Serum osteocalcin (OC) level and Alkaline phosphatase (ALP)
activity, sensitive biochemical markers of bone formation,10
were measured using the rat osteocalcin ELISA kit (Biomedi-
cal Technologies Inc., Stoughton, USA) and Quanti-Chrome
ALP assay kits (DALP-250, BioAssay Systems, CA, USA),
according to the manufacturers’ instructions, respectively.
2.6. Biochemical markers of bone resorption10
2.6.1. Serum C-terminal telopeptide fragment of type I collagen
C-terminus (CTX) level
It was determined using commercial Rat Laps ELISA kits
(Nordic Bioscience Diagnostics, Herlev, Denmark).
2.6.2. Serum tartrate-resistant acid phosphatase 5b (TRACP
5b) level
It was determined using rat ELISA kits (IDS Ltd., Boldon,
UK).
2.6.3. Urinary deoxypyridinoline (DPD) cross-links
DPD content as a bone absorption marker was determined by
ELISA using a commercial kit (Metra, San Diego, CA, USA),
and corrected for urinary creatinine measured by quantitative,
colorimetric assay, and was expressed as nanomole (nmol) per
milli mole (mmol) of urinary creatinine.2.7. Utero- and vagino trophic assay, measured by
2.7.1. Uterine and vaginal wet weights
At the end of our study, all animals were sacrificed. The uter-
ine and vaginal tissues were quickly dissected and weighed.
Wet wts. were recorded in grams after removal of associated
fat and luminal fluids. The standardized uterine index was cal-
culated based on uterine wet wt. (mg)-to-body weight (g) ratios
and multiplied by 100.11
2.7.2. Uterine Eosinophil peroxidase assay
A marker enzyme for uterine growth, was extracted and
assayed as described by Farley et al.12
2.7.3. Estrogen receptor (ER)–binding assay in uterine and
vaginal tissues
Uterine and vaginal tissues were minced and homogenized in
10 volumes of buffer A [25 mm Tris–HCl, 1.5 mm EDTA,
10 mm a-monothioglycerol, 10% glycerol, 10 mM sodium
molybdate (pH 7.4)], and the homogenates were centrifuged
at 105,000g for 60 min. The steroid-binding assay was per-
formed with freshly prepared cytosol. [3H]E2 binding was mea-
sured using the dextran-coated charcoal absorption technique
as described by Martel et al.13 and Asselin et al.14 The protein
concentration of cytosol was determined using the method of
Bradford with BSA as standard.15
2.7.4. Vaginal glycogen assay
Glycogen content in the female reproductive tract is important
for energy-consuming events, so it is a critical biomarker in
normal and disease conditions.16 Vaginal glycogen was esti-
mated by the method of Hassid and Abraham,17 as modified
by Morales et al.18
3. Statistical analysis
The results were expressed as mean ± standard deviation
(SD). All experimental data were analyzed using one-way anal-
ysis of variance (ANOVA). Probability values (P) of <0.05
were considered to be statistically significant. Data were ana-
lyzed by GraphPad Prism software, release 4.0 (GraphPad
Software, San Diego, CA).
4. The results
4.1. Experiment I: selection of the appropriate CE dose Fig. 1
Using the lowest effective CE dose, that is better tolerated with
fewer adverse effects, it remains a fundamental tenet of clinical
practice and a valuable goal in the treatment of post-
menopausal women. Based on the uterine wet wt., 0.05 mg/kg
fails to increase the uterine wt., and demonstrated wt. statisti-
cally similar to the VCD group. Higher CE doses (0.5, 2.5, 5
and 10 mg/kg) used in the present study, resulted in dose depen-
dent significant increase in uterine wet wt., compared to the
VCD treated group. Minimal uterine stimulation was observed
with CE 0.5 mg/kg and maximal was observed with CE 10 mg/
kg, which was similar to that seen with E25 lg/kg. We chose to
proceed with 0.5 mg/kg/d of CE given for 2 weeks as our estro-
genic dose for future combination studies with RLX.
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RLX dose Fig. 2
According to our results, RLX at doses, 0.3 and 3 mg/kg/d,
failed to completely antagonize the CE induced uterine effect,
and uterine wet wt. recorded significant increase compared to
the VCD treated group, while 10 mg/kg/d RLX fully antago-
nized the CE-induced increase in uterine wet wt., lowering
uterine wet wt. to level statistically similar to the vehicle. As
a result, 10 mg/kg/d RLX was chosen for future studies.
4.3. Experiment III
4.3.1. Effect of the CE/RLX TSEC on bone turnover markers in
VCD treated rats Figs. 3 and 4
As in postmenopausal women, the VCD induced estrogen defi-
ciency in rats produced a high turnover state, with accelerated
bone loss. All bone resorping parameters, increased signifi-
cantly in VCD-induced state, where serum CTX and TRACP
5b levels increased by about 1.9- and 2.3-folds respectively,
along with increased urinary DPD by about 3.1-fold, in
VCD -treated group compared to the control normal group.
The increased bone resorption observed in our model, was
associated with significant elevation in the sensitive biochemical
markers of bone formation, where serum OC and ALP levels,
were increased by 1.7- and 1.8-folds, respectively, in VCD trea-
ted rats compared to the control normal group. It is obvious
from our results that bone loss in the VCD treated rats parallels
with the early skeletal changes observed immediately in post-
menopausal women, who typically have a high rate of bone
remodeling with bone resorption exceeding bone formation.19
To evaluate the bone sparing effects, the CE (0.5 mg/kg/d)
and RLX (10 mg/kg/d) treatments, were continued for
12 weeks, either alone or combined as TSEC, to VCD-
treated rats.
The results of the current work showed that both CE and
RLX treatments, either alone or combined, were associated
with suppression of BTM to values statistically comparable
to that observed in the positive control, which was suggestive
of a full estrogen agonist effect of RLX on bone, an effect that
was preserved when combined with CE.Figure 1 Selection of the appropriate CE dose. Effect of different d
represented as mean ± SD, of 10 rats in each group. Significance was c
control group. #Significantly different from vehicle – treated VCD gr4.3.2. The uterine effects of the CE/RLX TSEC in VCD treated
rats Fig. 5
The additional important target site to investigate the potential
application of appropriate RLX/CE dose combination for the
postmenopausal women is the endometrial safety, so we inves-
tigated the effect of RLX and CE on estrogen sensitive uterine
parameters.
As obvious from our results, the VCD-induced estrogen
deficiency, resulted in reduction in uterine index by about
74.1%, along with 89.4% reduction in uterine eosinophil per-
oxidase activity that was associated with compensatory
increase in ERs protein level, compared to the control normal
group.
In contrast to the full estrogen agonist activity of CE on
endometrial profile in CE-treated VCD group, which recorded
significant increase in estrogen sensitive uterine parameters,
RLX alone resulted in distinct neutral uterine effects, with
uterine index, eosinophil Peroxidase activity, statistically simi-
lar to the vehicle-treated VCD group. Uterine ER protein
levels were significantly down regulated with both CE and
RLX treated VCD groups.
Our findings characterize a novel phenotype of the endome-
trial markers of estrogen agonist activity, when RLX and CE
combined appropriately, the RLX completely obliterated the
CE – induced increase in uterine index and eosinophil Peroxi-
dase activity, to levels statistically similar to the VCD group,
with reduction in ER protein level, that remained statistically
elevated relative to E2 treated VCD group.
4.3.3. The vaginal effects of the CE/RLX TSEC in VCD treated
rats Fig. 6
The question to be addressed was whether the bone sparing
effect of the combined RLX and CE could prevent the post-
menopausal associated vaginal atrophy or could aggravate
the condition, so we evaluated the effect of the RLX/CE TSEC
on vaginal tissue.
The VCD induced estrogen depletion, resulted in significant
reduction in vaginal wet wt. and glycogen content of 26.89
± 3.356, and 0.857 ± 0.2099 compared to 64.16 ± 1.567,
and 2.11 ± 0.4675, in the control normal group respectively,
associated with significant increase in vaginal ER (21.982oses of CE on uterine wet weight in VCD-treated rats. Data are
onsidered at level of P < 0.05. *Significantly different from normal
oup. @Significantly different from E2 treated group.
Figure 2 Selection of the minimum fully antagonist RLX dose. Effect of different RLX doses on estrogen stimulated uterine weight.
Data are represented as mean ± SD, of 10 rats in each group. Significance was considered at level of P < 0.05. *Significantly different
from normal control group. #Significantly different from vehicle – treated VCD group. @Significantly different from E2 – treated VCD
group. | Significantly different from CE- treated VCD group.
Figure 3 Serum markers of bone formation in all studied groups. Data are represented as mean ± SD, of 10 rats in each group.
Significance was considered at level of P < 0.05. *Significantly different from normal control group. #Significantly different from vehicle –
treated VCD group. Significantly different from E2 – treated VCD group.
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mal group.
In contrast to the estrogen agonist activity of CE on vaginal
parameters in VCD group, presented in significant increase in
vaginal wet wt., glycogen content, RLX alone resulted in obvi-
ous neutral vaginal effects, with vaginal wet wt., glycogen con-
tent, statistically similar to the VCD group. Both CE and RLX
were accompanied by significant reduction in the vaginal ER
levels compared to VCD group.
The RLX/CE TSEC preserved slight vaginotropic activity
with significant increase in vaginal wet wt. and glycogen con-
tent (28.490 ± 1.247 and 1.171 ± 0.4202), compared to
26.89 ± 3.356 and 0.857 ± 0.2099, in VCD group respectivelywith significant decrease in vaginal ER level of 16.938 ± 1.929,
compared to 21.982 ± 2.721, in VCD group.5. Discussion
The TSEC approach is a new therapeutic strategy of the post-
menopausal manifestations, based on the simultaneous but dif-
ferential effects of each compound on ER activity.
This study highlighted the potential for an optimal RLX/
CE combination that may provide the benefits of HRT with
eliminated or reduced oncogenic potential, in an attempt to
gain the benefits of each with better overall tolerability.
Figure 4 Bone resorping parameters in all studied groups. Data are represented as mean ± SD, of 10 rats in each group. Significance
was considered at level of P < 0.05. *Significantly different from normal control group. #Significantly different from vehicle – treated
VCD group.
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estrogen withdrawal is responsible for bone loss, and has been
claimed to be a risk factor in bone fractures.10
Our study revealed drastic decrease in bone turnover in
VCD treated groups, with CE, RLX, or both, reflecting an
important reduction in bone remodeling and increased bone
mineral density.1
The mechanisms underlying the bone sparing effect of
RLX/CE TSEC are still poorly understood. Recent reports
reveal increasing complexity of these mechanisms that imply
direct and indirect activities on bone cells.20
The bone anabolic effect of both RLX and estrogen,
through direct action on bone cells was previously confirmed
in a concentration-dependent manner, and was blocked by
the ER antagonist, ICI 164,384.21
Emerging evidence has shown that inhibition of osteoclas-
togenesis is the main mechanism by which estrogen andRLX prevent bone loss, directly by potently suppressing osteo-
clast differentiation induced by the ligand of receptor activator
of NF-rB (RANKL) and macrophage-colony stimulating fac-
tor (M-CSF), through the classical ER – and in dose-
dependent manner.22 These effects are mediated, at least in
part, through down regulation and repression in the level
and functional activity of c-fos and c-jun and osteoclast adhe-
sion through modulating their mode of interaction with the
bone microenvironment,23 possibly by decreasing the
expression of mRNA and protein of b3-integrin, in a time-
dependent manner, which has been identified as major func-
tional adhesion receptor in osteoclast.24
Preclinical data, either in vivo25 or in vitro19 showed that
RLX, similar to E2 could affect osteoclastic differentiation
and activity, indirectly through reducing level of proinflamma-
tory cytokines, especially IL-6 and TNF-a, and TGF-b1, and
increased insulin-like growth factor-1 that originate from
Figure 5 The uterine parameters in all studied groups. Data are represented as mean ± SD, of 10 rats in each group. Significance was
considered at level of P < 0.05. *Significantly different from normal control group. #Significantly different from vehicle – treated VCD
group. Significantly different from E2 – treated VCD group.
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bone resorption. This explanation has been defined in a series
of clinical studies in postmenopausal women.26
Beside the anti-resorptive action of RLX/CE, it has osteo-
blast stimulatory role through increased osteoblast-specific
Core binding factor 1 (Cbfa1)/runt-related transcription factor
2 (Runx2) and alpha2 procollagen type I chain mRNAs, that
have been identified as ‘‘master genes” in osteoblastic
differentiation.27
It has also been shown that RLX and estrogen enhance
osteoprotegerin (OPG) production from osteoblasts, as
demonstrated in vitro19 and in vivo.28 OPG is a post-
translationally glycolized protein that binds (RANKL) in com-
petitive inhibition manner. Lowering RANKL to OPG ratio
by RLX and estrogen is associated with enhanced osteoblastic
activity, preserved bone mineral density, blocked osteoclasticdifferentiation and modulation of osteoclastic apoptosis,
improving osteoporosis.19
Gallant et al.,29 have shown that RLX, similar to estrogen
acts directly on the bone matrix to improve material proper-
ties, specifically the modulus of toughness, a measure of the
ability of the tissue to absorb energy prior to fracture, indepen-
dently of bone mass and architecture, elucidating another pos-
sible mechanism of RLX bone anabolic effect.
Another indirect delayed mechanism of the bone-restoring
activity of RLX26 and estrogen28 could be attributed to change
of calcium metabolism at the level of the intestine, kidneys and
parathyroid, through suppression of parathyroid hormone and
induction of 25-OH vitamin D.
Our results are consistent with series of earlier in vivo stud-
ies in both OVX animals30 and postmenopausal women with31
and without osteoporosis,25 where RLX, similar to estrogen
Figure 6 The vaginal parameters in all studied groups. Data are represented as mean ± SD, of 10 rats in each group. Significance was
considered at level of P < 0.05. *Significantly different from normal control group. #Significantly different from vehicle – treated VCD
group. Significantly different from E2 – treated VCD group.
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decrease BTM and inhibit accelerated bone resorption.
Whereas RLX produced effects very similar to those of E2
and CE on bone, there is a striking difference in the effects of
these compounds on uterine tissue, as RLX lacked uterotropic
activity of estrogen, with neutral effects, when administered
alone compared to the VCD control group.
The mechanisms of the tissue-selective action of RLX,
although still only partly understood, can be explained based
on the mounting evidence that the ER does not act in the same
way in all target tissues and RLX has different affinities for
different ERs subtypes,28 leading to different conformations,
different coactivator associations, different affinities for differ-
ent gene promoters, yielding peculiar gene regulation, includ-
ing estrogen metabolizing genes.32Our results provide an interesting initial step in profiling
uterine effects of the RLX/CE TSEC, that protect the endome-
trium from the unopposed estrogenic stimulation, and would
therefore provide endometrial protection without counteract-
ing the positive effects of estrogens on bone, and vagina.
The mechanisms of action of RLX/CE TSEC are not clear
and resolution of a specific mechanism to describe its activities
is difficult as both components of the TSEC compete for the
same ligand binding pocket on the ERs.
The favorable endometrial safety profile of RLX/CE
TSEC, would be attributed to blocking of the estrogen-
induced DNA transcription, through competitive binding of
RLX to the ER,20 that has been essentially attributed to the
peculiar orientation and interaction of the critical alky-
laminoethoxy RLX side-chain with the amino acid aspartate
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ER.28 Moreover crystallographic studies have confirmed that
the RLX-ER complex demonstrates that Helix 12 becomes
reoriented and cannot seal the pocket containing the ligand,
because RLX side-chain is large and inflexible, which blocks
its possible interaction with activation factors-2 (AF-2) region,
so that coactivators cannot form a transcription complex, and
estrogen signal transduction is blocked. It appears that RLX
more strongly recruits co-repressor proteins and consequently
is still an antagonist in the uterus despite the higher concentra-
tion of co-activators relative to co-repressors.33
RLX competitive antagonistic effect has been proved previ-
ously by Wardell et al.34 who stated that E2 – induced tran-
scriptional response is completely reversed by RLX, and that
the expression level of genes in the presence of E2 together
with RLX is not distinguishable from the basal level. Giner
et al.19 claimed that RLX may act, directly or indirectly at
the post-transcriptional level, blocking the estrogen effects.
RLX component of TSEC could mediate its effects, like E2,
through nongenomic actions, that are frequently associated
with the activation of various protein-kinase cascades, inde-
pendent of the ER-ligand complex induced nuclear transcrip-
tion properties.35
Although several data revealed that RLX’s action is ER
mediated, non-ER-based mechanisms, cannot be ruled out as
suspected by Bjornstrom et al.35
To further demonstrate the underlying mechanism, through
which the RLX or estrogen mediates their effects, uterine and
vaginal ERs were assayed.
In the current study, ER protein levels in uterine tissue were
downregulated in the presence of its cognate ligand, E2, and
were significantly lower with RLX and RLX/CE compared
to control VCD group. This finding suggests that RLX
actions, similar to estrogen, are mediated through high affinity
to ERs and may facilitate ubiquitarian and protea some-
mediated ER degradation.33
ERs have emerged as ligand-dependent transcriptional acti-
vator, whose expression is regulated by native E2, in a recipro-
cal manner. Estrogen-deficient animals express higher amounts
of functional ER that may serve as a homeostatic mechanism
to buffer against decreased estrogen levels. Moreover ERa
mRNA increases in postmenopausal women who are not
receiving hormone therapy, and decreases to levels similar to
those found in premenopausal women, with systemic HRT.11
Our results support a small body of prior evidence from cell
culture,20 experimental and clinical studies33 conducted on
RLX and estrogen, demonstrating that RLX shows either neu-
trality or an estrogen antagonist, blocking the estradiol-induced
effects in the uterus. Moreover RLX wasn’t associated with,
and may even be effective at, preventing endometrial cancer.33
Despite the fact that the vagina is a classic estrogen-
responsive organ, it has received little attention compared to
the adjacent uterus.
In our study, unlike the agonist effect of estrogen or neutral
effect of RLX, the RLX/CE TSEC had unique vaginal profile,
which supports its potential use for treating VVA in post-
menopausal women.
Our results are in accordance with those obtained from pre-
clinical experiments and clinical data showing that RLX has
neutral effect on vagina.2
Together with the slight but significant increase in vaginal
wet wt., the RLX/CE TSEC treatment also resulted in anincrease in vaginal glycogen content. Glycogen-consuming
Lactobacilli can then colonize the vagina and lower the vaginal
pH by catabolism of glycogen into lactic acid, generating an
acidic environment, that plays an important role in maintain-
ing the health of the lower genital tract in women.2 The signif-
icant reduction in vaginal ER protein level in all treated VCD
groups, indicating that RLX, similar to estrogen exerted ERs
mediated effects.
Indeed, data obtained from randomized, double-blind clin-
ical trials, support the possibility of safely use of RLX together
with estrogen in postmenopausal women with vaginal atro-
phy,5 where RLX did not alter the effects of the estrogen in
alleviating genitourinary atrophy, and had no negative effects
on sexual function.66. Conclusion and recommendation
Data from our study demonstrated that a combined RLX/CE
TSEC given at an appropriate dose may dominate the estrogen
phenotype in bone with more favorable profiles in the endome-
trium and vagina and may be used as alternatives in future
postmenopausal therapies. Further studies directly comparing
different RLX doses and estrogen combinations are needed to
identify the safest combination dosage for this purpose, that
would demonstrate efficacy with minimal to no stimulation
of the breast or endometrium, and elucidate the possible long
term clinical advantages and side effects over presently avail-
able treatment modalities.Conflict of interest
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